Role of CXCR2 Ligands/CXCR2 Biological Axis in Pancreatic Cancer - Full Text View

Sponsored by:	Mayo Clinic
Information provided by:	Mayo Clinic
ClinicalTrials.gov Identifier:	NCT00851955

Purpose

The investigators hypothesize that the CXCR2 ligands/CXCR2 biological axis plays an important role in promoting angiogenesis in PC; and that the genetic changes and the microenvironment of the tumor regulate the expression of CXCR2 ligands/CXCR2 in PC in order to potentiate their angiogenic phenotype. A corollary of this hypothesis is that the cell surface receptors (CXCR2) and the intracellular signaling pathways that mediate the angiogenic responses induced by ELR+ CXC-chemokines are potential targets for novel therapeutic interventions in PC.

Condition
Chronic Pancreatitis Pancreatic Cancer

Study Type:	Observational
Study Design:	Case-Only, Prospective
Official Title:	Role of CXCR2 Ligands/CXCR2 Biological Axis in Pancreatic Cancer

Resource links provided by NLM:

MedlinePlus related topics: Cancer Pancreatic Cancer

U.S. FDA Resources

Further study details as provided by Mayo Clinic:

Primary Outcome Measures:

All cause mortality [ Time Frame: One year ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

For pancreatic patients from whom tissue samples will be available, we will examine the association between presence/absence of each marker in the tissue versus the marker level in blood and in pancreatic juice. [ Time Frame: One year ] [ Designated as safety issue: No ]

Estimated Enrollment:	150
Study Start Date:	May 2007

Groups/Cohorts
1. Normal pancreas patients Patients with no documented clinical history of pancreatic diseases supported by at least 1 negative imaging test (EUS, CT scan or MRI).
2. Chronic pancreatitis patients Patients with documented diagnosis of moderate to advanced chronic pancreatitis supported by at least 1 positive imaging test (EUS,CT scan or MRI).
3. Pancreatic cancer patients Patients with documented tissue diagnosis (or clinical suspicion) of Pancreatic Cancer.

Eligibility

Ages Eligible for Study:	18 Years to 90 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes
Sampling Method:	Probability Sample

Study Population

Primary Care

Criteria

Inclusion Criteria:

Normal subjects - No documented clinical history of pancreatic diseases supported by at least 1 negative imaging test. (EUS, Ct scan or MRI)
Chronic pancreatitis - Documented diagnosis of moderate to advanced chronic supported bpancreatitisy at least 1 positive imaging test. (EUS, Ct scan or MRI)
Pancreatic Cancer - Documented tissue diagnosis (or clinical suspicion) of Pancreatic Cancer.

Exclusion Criteria:

Exclusion criteria will include age younger than 18 yrs, pregnancy, previous pancreatic or gastric resection, and inability to tolerate routine endoscopy with conscious sedation

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00851955

Contacts

Contact: Massimo Raimondo, MD	904-953-2000	Raimondo.massimo@mayo.edu
Contact: Verna A. Skinner, CCRP	904-953-8982	skinner.verna@mayo.edu

Locations

United States, Florida
Mayo Clinic	Recruiting
Jacksonville, Florida, United States, 32224
Contact: Verna A. Skinner, CCRP 904-953-8982 skinner.verna@mayo.edu

Sponsors and Collaborators

Mayo Clinic

Investigators

Principal Investigator:

Massimo Raimondo, MD

Mayo Clinic

More Information

No publications provided

Responsible Party:	ChiRhoClin, Inc. ( ChiRhonClin )
Study ID Numbers:	07-000099
Study First Received:	February 25, 2009
Last Updated:	February 25, 2009
ClinicalTrials.gov Identifier:	NCT00851955 History of Changes
Health Authority:	United States: Food and Drug Administration; United States: Federal Government

Study placed in the following topic categories:

Digestive System Diseases
Digestive System Neoplasms
Pancreatic Neoplasms
Endocrine System Diseases
Pancreatic Diseases

Gastrointestinal Neoplasms
Endocrinopathy
Pancreatitis
Endocrine Gland Neoplasms
Pancreatitis, Chronic

Additional relevant MeSH terms:

Neoplasms
Digestive System Diseases
Neoplasms by Site
Digestive System Neoplasms
Pancreatic Neoplasms

Endocrine System Diseases
Pancreatic Diseases
Pancreatitis
Endocrine Gland Neoplasms
Pancreatitis, Chronic

ClinicalTrials.gov processed this record on September 10, 2009